
The growth strategy said resilient biopharma demand and healthy third-quarter guidance supported its outlook for improving business into 2027.
ClearBridge Investments said Thermo Fisher Scientific was a positive contributor in the third quarter of 2026, citing resilient demand and healthy guidance.
In its investor letter, the growth strategy said the company benefited from its second-quarter earnings beat. It pointed to demand for biopharma consumables and pharmaceutical product development.
ClearBridge said the breadth of recovery in those markets was important after a difficult period for life sciences spending. It said the trends supported the prospect of an accelerating business into 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.